Cystatin A

A cytastin subtype found at high levels in the SKIN and in BLOOD CELLS. Cystatin A incorporates into the cornified cell envelope of stratified squamous epithelial cells and may play a role in bacteriostatic properties of skin.

Also Known As:

Networked: 115 relevant articles (1 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kos, Janko: 8 articles (11/2013 - 01/2000)
2.	Li, Jun: 3 articles (03/2022 - 11/2014)
3.	Lah, Tamara T: 3 articles (05/2010 - 01/2002)
4.	Kos, J: 3 articles (03/2001 - 01/2000)
5.	John Mary, Dixcy Jaba Sheeba: 2 articles (01/2020 - 12/2017)
6.	Kumar, Ajay: 2 articles (01/2020 - 12/2017)
7.	Parker, Belinda S: 2 articles (12/2017 - 03/2012)
8.	Sloane, Bonnie F: 2 articles (12/2017 - 03/2012)
9.	Cai, Yonglin: 2 articles (01/2015 - 11/2014)
10.	Gao, Jianquan: 2 articles (01/2015 - 11/2014)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1980 - "[Demonstration of an epidermal SH-protease inhibitor in normal epithelium and in some human neoplasms--an immunological study (author's transl)]." 01/01/2015 - "Both MIP-3α and cystatin A overexpressions in NPC tumor tissues were strong independent factors of poor prognosis in NPC patients. " 01/01/2015 - "Cell cycle- and cancer-associated gene networks activated by Dsg2: evidence of cystatin A deregulation and a potential role in cell-cell adhesion." 10/01/2011 - "Using the stefin A concentration difference in matched pairs of tissue samples as a stratifying variable, 53 cases were found to be upregulated (higher concentrations in tumor samples than in nontumorous mucosa) and 39 cases downregulated. " 08/01/2007 - "Stefin A was upregulated in 53 patients (higher concentrations were measured in tumor samples than in nontumorous mucosa) and was downregulated in 39 patients. "
2.	Neoplasm Metastasis (Metastasis) 01/01/2023 - "In this study, Cystatin A (CSTA) was found downregulated in NPC tissues with metastasis compared with those without metastasis. " 03/01/2019 - "Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial." 11/01/2014 - " results revealed that serum MIP-3α and cystatin A may be promising candidate prognostic factors for NPC, and higher serum levels of MIP-3α and cystatin A correlate with shorter probability of OS, local recurrence, and distant metastasis. " 11/01/2014 - "In addition, serum pretreatment MIP-3α and cystatin A levels were independent prognostic factors for OS and distant metastasis-free survival of NPC patients; serum posttreatment MIP-3α and cystatin A levels were independent prognostic factors of local recurrence-free survival.Our" 11/01/2014 - "Patients with high serum level of MIP-3α and cystatin A before treatment had poorer overall survival (OS), local recurrence-free survival, and distant metastasis-free survival than the ones with low level. "
3.	Carcinoma (Carcinomatosis) 08/01/2007 - "Stefin A was recognized as a promising candidate marker for prognosis in patients with operable carcinoma of the head and neck." 03/01/2003 - "Cystatin A was expressed in the basal cells in all cases of BPH, low-grade PIN, and high-grade PIN whereas carcinomas showed no staining of cystatin A. " 03/01/2003 - "Previously it has been shown that cystatin A is expressed in the basal cells of normal prostate and the expression disappears in prostatic carcinoma. " 02/01/1998 - "This type of carcinoma may develop during tumor progression through genetic instability that allows cystatin A expression and gives growth advantage to a clone of tumor cells." 08/01/2007 - "The aim of this study was to test the hypothesis about the protective role of high stefin A and stefin B concentrations in operable carcinoma of the head and neck. "
4.	Prostatic Neoplasms (Prostate Cancer) 09/15/2001 - "This is the first report to define heterogeneity within any Gleason score for prostate cancers by the ratios of CB to stefin A." 09/15/2001 - "Statistical analyses showed prostate cancer cases with ratios of CB > stefin A (P < 0.05) and CB < stefin A (P < 0.05) significantly different from normal prostate and BPH which had ratios of CB = stefin A. " 09/15/2001 - "We found considerable variability in individual localization of CB and stefin A within and between Gleason histologic scores for prostate cancers. " 09/15/2001 - "Our objective was to identify patterns of distribution of CB and its endogenous cellular inhibitor stefin A in cryostat sections of frozen BPH and prostate cancer tissue samples and to define these patterns in relation to Gleason histologic scores, clinical stages, and serum total PSA levels. " 07/01/1999 - "Our data showed that there were prostate cancer cases within Gleason histologic scores which expressed high, similar, and low levels of CB when compared to stefin A. "
5.	Nasopharyngeal Carcinoma 01/01/2015 - "This study aims to investigate the expression of macrophage inflammatory protein-3 alpha (MIP-3α) and cystatin A in nasopharyngeal carcinoma (NPC) and their association with clinical characteristics and prognosis. " 11/01/2014 - "This study was aimed to investigate the roles of serum macrophage inflammatory protein-3α (MIP-3α) and cystatin A in nasopharyngeal carcinoma (NPC) prognosis.The" 01/01/2015 - "Expression and Prognostic Significance of Macrophage Inflammatory Protein-3 Alpha and Cystatin A in Nasopharyngeal Carcinoma." 11/01/2014 - "Increased serum levels of macrophage inflammatory protein-3α and cystatin a predict a poor prognosis of nasopharyngeal carcinoma." 07/01/2010 - "Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis."

Related Drugs and Biologics

1.	Cystatin B
2.	Cystatins
3.	Cathepsin B
4.	Cysteine Proteases (Cysteine Protease)
5.	Proteins (Proteins, Gene)
6.	Cystatin C
7.	Cathepsin L
8.	Cathepsins
9.	Cysteine Proteinase Inhibitors
10.	Enzymes

Related Therapies and Procedures

1.	Therapeutics
2.	Chemoradiotherapy
3.	Intraventricular Infusions
4.	Highly Active Antiretroviral Therapy (HAART)
5.	Prostatectomy (Retropubic Prostatectomy)